Vertex Pharmaceuticals Incorporated Peer Comparison

Metric Value Ranking
Market Cap $131.4 Billion 1/21 VRTX
$131.4B		 REGN
$71.1B		 SGEN
$43.2B		 ALNY
$36.5B		 BNTX
$23.3B		 BMRN
$13.6B		 MRNA
$13.1B		 MDGL
$7.6B		 SRPT
$7.4B		 RETA
$6.6B		 KRYS
$5.5B		 PTCT
$4.5B		 CRSP
$3.5B		 VKTX
$3.3B		 BEAM
$2.3B		 NTLA
$903.7M		 ICPT
$794.7M		 VERV
$513.2M		 DNA
$391.8M		 EDIT
$107.9M		 CRBU
$89.3M
Gross Margin 85% 13/21 ICPT
100%		 EDIT
100%		 NTLA
100%		 CRSP
100%		 BEAM
100%		 CRBU
100%		 VERV
100%		 MDGL
97%		 RETA
96%		 KRYS
95%		 REGN
93%		 PTCT
92%		 VRTX
85%		 ALNY
83%		 BMRN
82%		 SRPT
80%		 BNTX
80%		 DNA
78%		 SGEN
75%		 MRNA
23%		 VKTX
0%
Profit Margin 31% 3/21 RETA
100%		 KRYS
50%		 VRTX
31%		 REGN
24%		 SRPT
24%		 BNTX
22%		 BMRN
17%		 VKTX
0%		 ICPT
-3%		 ALNY
-14%		 PTCT
-31%		 SGEN
-33%		 MDGL
-58%		 EDIT
-100%		 NTLA
-100%		 CRSP
-100%		 MRNA
-100%		 BEAM
-100%		 CRBU
-100%		 VERV
-100%		 DNA
-100%
EBITDA margin 41% 2/21 KRYS
47%		 VRTX
41%		 BNTX
39%		 REGN
26%		 SRPT
25%		 BMRN
22%		 ICPT
-3%		 PTCT
-22%		 ALNY
-26%		 SGEN
-34%		 MDGL
-54%		 VKTX
-100%		 EDIT
-108%		 MRNA
-129%		 CRSP
-171%		 BEAM
-282%		 DNA
-327%		 RETA
-356%		 VERV
-416%		 NTLA
-1040%		 CRBU
-1815%
Quarterly Revenue $2.9 Billion 2/21 REGN
$3.8B		 VRTX
$2.9B		 BNTX
$1.3B		 MRNA
$966.0M		 BMRN
$747.3M		 SRPT
$658.4M		 SGEN
$648.7M		 ALNY
$593.2M		 PTCT
$213.2M		 MDGL
$103.3M		 KRYS
$91.1M		 ICPT
$88.8M		 DNA
$43.8M		 CRSP
$35.0M		 EDIT
$30.6M		 BEAM
$30.1M		 RETA
$22.7M		 VERV
$13.1M		 NTLA
$12.9M		 CRBU
$2.1M		 VKTX
$0
Quarterly Earnings $913.0 Million 2/21 REGN
$917.7M 		VRTX
$913.0M 		BNTX
$285.2M 		RETA
$193.0M 		SRPT
$159.0M 		BMRN
$124.9M 		KRYS
$45.5M 		ICPT
-$2.8M 		VKTX
-$35.4M 		CRBU
-$35.5M 		CRSP
-$37.3M 		EDIT
-$45.4M 		VERV
-$50.0M 		MDGL
-$59.4M 		PTCT
-$65.9M 		ALNY
-$83.8M 		BEAM
-$90.4M 		DNA
-$107.5M 		NTLA
-$128.9M 		SGEN
-$215.8M 		MRNA
-$1.1B
Quarterly Free Cash Flow $492.0 Million 1/21 VRTX
$492.0M 		SRPT
$54.0M 		KRYS
$52.0M 		ICPT
$3.9M 		VKTX
-$31.2M 		CRBU
-$36.0M 		PTCT
-$36.5M 		VERV
-$42.2M 		CRSP
-$50.3M 		EDIT
-$51.3M 		DNA
-$56.1M 		RETA
-$70.2M 		BEAM
-$79.3M 		SGEN
-$79.8M 		NTLA
-$86.2M 		ALNY
-$103.8M 		MDGL
-$104.7M 		BNTX
-$609.2M 		BMRN
-$0 		REGN
-$0 		MRNA
-$0
Trailing 4 Quarters Revenue $11.0 Billion 3/21 BMRN
$736.0B		 REGN
$14.2B		 VRTX
$11.0B		 MRNA
$3.2B		 BNTX
$3.0B		 SGEN
$2.3B		 ALNY
$2.2B		 SRPT
$1.9B		 PTCT
$745.4M		 KRYS
$329.1M		 ICPT
$317.7M		 DNA
$227.0M		 MDGL
$180.1M		 BEAM
$63.5M		 NTLA
$57.9M		 CRSP
$36.6M		 VERV
$32.3M		 EDIT
$32.3M		 RETA
$24.4M		 CRBU
$10.0M		 VKTX
$0
Trailing 4 Quarters Earnings -$535.6 Million 17/21 REGN
$3.8B 		VRTX
$2.9B 		BNTX
$1.3B 		MRNA
$966.0M 		BMRN
$747.3M 		SRPT
$658.4M 		SGEN
$648.7M 		ALNY
$593.2M 		PTCT
$213.2M 		MDGL
$103.3M 		KRYS
$91.1M 		ICPT
$88.8M 		DNA
$43.8M 		CRSP
$35.0M 		EDIT
$30.6M 		BEAM
$30.1M 		RETA
$22.7M 		VERV
$13.1M 		NTLA
$12.9M 		CRBU
$2.1M 		VKTX
-$0
Quarterly Earnings Growth -6% 11/21 KRYS
4780% 		RETA
362% 		SRPT
248% 		PTCT
58% 		DNA
49% 		MDGL
47% 		ALNY
39% 		NTLA
2% 		CRBU
-3% 		VERV
-3% 		VRTX
-6% 		SGEN
-13% 		REGN
-21% 		BNTX
-43% 		VKTX
-44% 		BMRN
-99% 		ICPT
-101% 		EDIT
-141% 		CRSP
-142% 		BEAM
-163% 		MRNA
-616%
Annual Earnings Growth -113% 16/21 BMRN
419% 		SRPT
405% 		KRYS
327% 		RETA
72% 		MRNA
67% 		DNA
51% 		PTCT
35% 		REGN
5% 		NTLA
-4% 		VERV
-7% 		MDGL
-14% 		VKTX
-19% 		SGEN
-26% 		CRSP
-48% 		EDIT
-54% 		VRTX
-113% 		ICPT
-124% 		CRBU
-131% 		BEAM
-159% 		BNTX
-171% 		ALNY
-191%
Quarterly Revenue Growth 16% 9/21 RETA
2885% 		NTLA
772% 		VERV
154% 		KRYS
101% 		SRPT
66% 		ALNY
35% 		SGEN
27% 		DNA
26% 		VRTX
16% 		ICPT
14% 		REGN
10% 		VKTX
0% 		MDGL
0% 		BNTX
-20% 		PTCT
-31% 		CRBU
-42% 		EDIT
-49% 		MRNA
-66% 		CRSP
-83% 		BEAM
-90% 		BMRN
-100%
Annual Revenue Growth 10% 9/21 RETA
596% 		VERV
123% 		KRYS
92% 		NTLA
70% 		SRPT
37% 		SGEN
15% 		BMRN
14% 		DNA
13% 		VRTX
10% 		ICPT
8% 		REGN
5% 		VKTX
0% 		MDGL
0% 		PTCT
-17% 		ALNY
-19% 		BNTX
-34% 		EDIT
-46% 		MRNA
-61% 		CRSP
-82% 		BEAM
-83% 		CRBU
-87%
Cash On Hand $4.6 Billion 2/21 BNTX
$10.7B 		VRTX
$4.6B 		MRNA
$1.9B 		SRPT
$1.1B 		ALNY
$966.4M 		BMRN
$942.8M 		PTCT
$779.7M 		DNA
$561.6M 		SGEN
$428.6M 		KRYS
$344.9M 		CRSP
$298.3M 		BEAM
$282.0M 		NTLA
$189.2M 		VERV
$172.6M 		EDIT
$131.5M 		ICPT
$102.7M 		MDGL
$100.0M 		RETA
$48.8M 		VKTX
$26.7M 		CRBU
$16.3M 		REGN
-$0
Short Term Debt $92.3 Million 2/21 PTCT
$271.2M 		VRTX
$92.3M 		BNTX
$43.4M 		ALNY
$41.9M 		NTLA
$20.2M 		CRSP
$17.3M 		EDIT
$14.7M 		BEAM
$13.5M 		VERV
$10.4M 		RETA
$2.5M 		CRBU
$1.4M 		KRYS
$1.2M 		MDGL
$983,000 		VKTX
$489,000 		BMRN
-$0 		REGN
-$0 		SRPT
-$0 		SGEN
-$0 		ICPT
-$0 		MRNA
-$0 		DNA
-$0
Long Term Debt $1.7 Billion 3/21 PTCT
$2.2B		 REGN
$2.0B		 VRTX
$1.7B		 SRPT
$1.3B		 ALNY
$1.3B		 MRNA
$710.0M		 BMRN
$595.1M		 DNA
$438.8M		 BNTX
$235.9M		 ICPT
$223.9M		 CRSP
$206.4M		 NTLA
$190.0M		 RETA
$163.5M		 BEAM
$148.0M		 MDGL
$118.6M		 SGEN
$113.5M		 VERV
$59.5M		 CRBU
$25.1M		 EDIT
$20.4M		 KRYS
$6.0M		 VKTX
$630,000
PE -1.00 5/21 KRYS
48.00		 SRPT
31.48		 REGN
16.10		 BMRN
0.13		 VRTX
-1.00		 ALNY
-1.00		 VKTX
-1.00		 RETA
-1.00		 SGEN
-1.00		 ICPT
-1.00		 MDGL
-1.00		 PTCT
-1.00		 EDIT
-1.00		 NTLA
-1.00		 CRSP
-1.00		 MRNA
-1.00		 BEAM
-1.00		 BNTX
-1.00		 CRBU
-1.00		 VERV
-1.00		 DNA
-1.00
PS 11.94 10/21 RETA
269.17		 CRSP
95.77		 MDGL
42.08		 BEAM
36.50		 SGEN
18.76		 ALNY
16.86		 KRYS
16.83		 VERV
15.87		 NTLA
15.61		 VRTX
11.94		 CRBU
8.93		 BNTX
7.01		 PTCT
6.03		 REGN
5.00		 MRNA
4.04		 SRPT
3.89		 EDIT
3.34		 ICPT
2.50		 DNA
1.73		 BMRN
0.02		 VKTX
-1.00
PB 8.01 6/21 ALNY
544.74		 RETA
75.22		 SGEN
16.92		 ICPT
11.06		 MDGL
10.05		 VRTX
8.01		 KRYS
5.85		 SRPT
4.85		 VKTX
3.73		 BEAM
3.16		 BMRN
2.41		 REGN
2.03		 CRSP
1.82		 MRNA
1.20		 BNTX
1.09		 NTLA
1.04		 VERV
1.04		 EDIT
0.80		 DNA
0.55		 CRBU
0.35		 PTCT
0.00
PC 28.76 6/21 RETA
134.44		 VKTX
123.21		 SGEN
100.70		 MDGL
75.78		 ALNY
37.82		 VRTX
28.76		 KRYS
16.06		 BMRN
14.47		 CRSP
11.76		 BEAM
8.22		 ICPT
7.74		 MRNA
6.78		 SRPT
6.71		 PTCT
5.77		 CRBU
5.48		 NTLA
4.78		 VERV
2.97		 BNTX
2.17		 EDIT
0.82		 DNA
0.70		 REGN
-1.00
Liabilities to Equity 0.37 10/21 ALNY
62.20		 RETA
4.76		 ICPT
4.47		 SRPT
1.59		 EDIT
1.54		 DNA
0.92		 BEAM
0.50		 SGEN
0.42		 MDGL
0.38		 VRTX
0.37		 NTLA
0.37		 VERV
0.31		 MRNA
0.30		 BMRN
0.24		 CRBU
0.24		 CRSP
0.16		 BNTX
0.16		 KRYS
0.12		 REGN
0.08		 VKTX
0.03		 PTCT
0.00
ROA -0.02 5/21 BMRN
1522% 		REGN
12% 		KRYS
11% 		SRPT
6% 		VRTX
-2% 		BNTX
-3% 		ALNY
-7% 		VKTX
-12% 		ICPT
-15% 		RETA
-16% 		CRSP
-16% 		SGEN
-21% 		PTCT
-21% 		MRNA
-25% 		VERV
-31% 		BEAM
-34% 		DNA
-40% 		NTLA
-44% 		MDGL
-45% 		CRBU
-48% 		EDIT
-69%
ROE -0.03 6/21 BMRN
1881% 		PTCT
33% 		SRPT
15% 		REGN
13% 		KRYS
12% 		VRTX
-3% 		BNTX
-4% 		VKTX
-12% 		CRSP
-19% 		SGEN
-29% 		MRNA
-33% 		VERV
-40% 		BEAM
-51% 		CRBU
-59% 		NTLA
-60% 		MDGL
-62% 		DNA
-76% 		ICPT
-82% 		RETA
-94% 		EDIT
-177% 		ALNY
-415%
Current Ratio 3.68 11/21 VKTX
32.39		 REGN
13.50		 KRYS
9.65		 CRSP
7.23		 BNTX
7.22		 BMRN
5.25		 CRBU
5.19		 MRNA
4.36		 VERV
4.20		 NTLA
3.73		 VRTX
3.68		 MDGL
3.62		 SGEN
3.35		 BEAM
2.98		 DNA
2.08		 EDIT
1.65		 SRPT
1.63		 ICPT
1.22		 RETA
1.21		 ALNY
1.02		 PTCT
0.61
Quick Ratio 1.00 13/21 KRYS
48.00		 SRPT
31.48		 REGN
16.10		 BMRN
0.13		 VRTX
-1.00		 ALNY
-1.00		 VKTX
-1.00		 RETA
-1.00		 SGEN
-1.00		 ICPT
-1.00		 MDGL
-1.00		 PTCT
-1.00		 EDIT
-1.00		 NTLA
-1.00		 CRSP
-1.00		 MRNA
-1.00		 BEAM
-1.00		 BNTX
-1.00		 CRBU
-1.00		 VERV
-1.00		 DNA
-1.00
Long Term Debt to Equity 0.10 13/21 ALNY}
18.69		 ICPT}
3.12		 RETA}
1.87		 SRPT}
0.87		 DNA}
0.61		 NTLA}
0.22		 BEAM}
0.20		 MDGL}
0.16		 EDIT}
0.15		 VERV}
0.12		 BMRN}
0.11		 CRSP}
0.11		 VRTX}
0.10		 CRBU}
0.10		 MRNA}
0.07		 REGN}
0.06		 SGEN}
0.04		 KRYS}
0.01		 BNTX}
0.01		 VKTX}
0.00		 PTCT}
-2.00
Debt to Equity 0.11 12/21 ALNY
19.32		 ICPT
3.12		 RETA
1.90		 SRPT
0.87		 DNA
0.61		 EDIT
0.26		 NTLA
0.24		 BEAM
0.22		 MDGL
0.16		 VERV
0.14		 CRSP
0.12		 VRTX
0.11		 BMRN
0.11		 CRBU
0.10		 MRNA
0.07		 REGN
0.06		 SGEN
0.04		 KRYS
0.01		 BNTX
0.01		 VKTX
0.00		 PTCT
-2.25
Burn Rate -5.55 17/21 ICPT
8.75		 ALNY
6.69		 CRSP
5.98		 DNA
4.49		 PTCT
3.52		 VERV
3.14		 BEAM
2.83		 EDIT
2.64		 SGEN
1.95		 MRNA
1.68		 MDGL
1.55		 NTLA
1.34		 VKTX
0.75		 CRBU
0.44		 REGN
0.00		 RETA
-0.26		 VRTX
-5.55		 KRYS
-7.68		 BMRN
-9.32		 SRPT
-10.42		 BNTX
-36.60
Cash to Cap 0.03 15/21 DNA
1.43		 EDIT
1.22		 BNTX
0.46		 VERV
0.34		 NTLA
0.21		 CRBU
0.18		 PTCT
0.17		 SRPT
0.15		 MRNA
0.15		 ICPT
0.13		 BEAM
0.12		 CRSP
0.09		 BMRN
0.07		 KRYS
0.06		 VRTX
0.03		 ALNY
0.03		 VKTX
0.01		 RETA
0.01		 SGEN
0.01		 MDGL
0.01		 REGN
0.00
CCR 0.54 12/21 MDGL
1.76		 CRSP
1.35		 ALNY
1.24		 KRYS
1.14		 EDIT
1.13		 CRBU
1.01		 VKTX
0.88		 BEAM
0.88		 VERV
0.84		 NTLA
0.67		 PTCT
0.55		 VRTX
0.54		 DNA
0.52		 SGEN
0.37		 SRPT
0.34		 RETA
-0.36		 ICPT
-1.38		 BNTX
-2.14		 BMRN
 REGN
 MRNA
EV to EBITDA 108.44 2/21 KRYS}
121.16		 VRTX}
108.44		 BMRN}
82.39		 REGN}
73.77		 SRPT}
47.21		 BNTX}
34.64		 EDIT}
-0.34		 VKTX}
-1.00		 DNA}
-1.88		 CRBU}
-2.64		 NTLA}
-6.91		 VERV}
-7.55		 MRNA}
-9.50		 BEAM}
-25.88		 CRSP}
-57.46		 RETA}
-82.50		 PTCT}
-132.04		 MDGL}
-136.79		 SGEN}
-191.83		 ALNY}
-237.92		 ICPT}
-331.82
EV to Revenue 11.68 10/21 RETA
273.97		 CRSP
93.73		 MDGL
42.19		 BEAM
34.60		 SGEN
18.62		 ALNY
17.01		 NTLA
15.98		 KRYS
15.81		 VERV
12.70		 VRTX
11.68		 CRBU
9.95		 PTCT
8.30		 BNTX
5.32		 REGN
5.14		 SRPT
4.01		 MRNA
3.66		 ICPT
2.88		 DNA
1.18		 EDIT
0.35		 BMRN
0.02		 VKTX
-1.00

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions